Target is common shares; number of shares acquired is 57,400 shares; total acquisition amount is 186,619,000 yen. Acquisition period is 2026\/9\/1\u20132026\/9\/30, method is market purchase. At the board resolution on 2026\/3\/30, an upper limit of 530,000 shares, an upper limit total of 2,000,000,000 yen, and a period from 2026\/5\/18 to 2026\/12\/18 were approved. Cumulative total as of 2026\/9\/30 is 325,900 shares and 1,054,903,000 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4534-20261001-01.pdf","jir_short_summary":"Target is common shares; number of shares acquired is 57,400 shares; total acquisition amount is 186,619,000 yen. Acquisition period is 2026\/9\/1\u20132026\/9\/30, method is market purchase. At the board resolution on 2026\/3\/30, an upper limit of 530,000 shares, an upper limit total of 2,000,000,000 yen, and a period from 2026\/5\/18 to 2026\/12\/18 were approved. Cumulative total as of 2026\/9\/30 is 325,900 shares and 1,054,903,000 yen.","jir_summary":"### Overview of Capital Policy\nThe Company is conducting treasury stock acquisitions through market purchases, targeting common shares. As of September 30, 2026, a cumulative total of 325,900 shares have been acquired, with a total amount of 1,054,903,000 yen. The current acquisition period is from September 1, 2026 to September 30, 2026. At the most recent board resolution on March 30, 2026, approval was given for an upper limit of 530,000 shares, an upper limit total of 2,000,000,000 yen, and a period from May 18, 2026 to December 18, 2026. Depending on market conditions, some or all of the acquisitions may not be executed.\n\n### Impact on Shareholders and Outlook\nThis treasury stock acquisition is being implemented from the perspectives of curbing dilution and returning value to shareholders, and the cumulative number of shares acquired and total amount indicate progress against the disclosed upper limit. Specific dividend policy or future changes to capital policy are not stated in this document, but note that the Company may continue treasury stock acquisitions.","jir_financial_highlights":"Total number of shares acquired: 57,400 shares (Unknown)\nTotal acquisition amount: 186,619,000 yen (Unknown)\nAcquisition period: 2026-09-01\uff5e2026-09-30 (Unknown)\nCumulative number of shares acquired (as of 2026\/9\/30): 325,900 shares (Unknown)\nCumulative acquisition amount (as of 2026\/9\/30): 1,054,903,000 yen (Unknown)","jir_category":"","jir_hashtags":"#MochidaPharmaceutical TreasuryStockAcquisition","jir_key_figures":"57,400 shares: Number of shares acquired (this tranche)\n186,619,000 yen: Total acquisition amount of shares (this tranche)\n325,900 shares: Cumulative number of shares acquired (as of 2026\/9\/30)","jir_meta_title":"Mochida Pharmaceutical: Announcement of Treasury Stock Acquisition Status | September 2026","jir_meta_description":"Announcement of Mochida Pharmaceutical Co., Ltd.'s treasury stock acquisition status. Summary of number of shares acquired, total amount, period, and cumulative results to inform investors on shareholder returns and capital policy.","jir_og_title":"Announcement of Mochida Pharmaceutical Treasury Stock Acquisition Status | September 2026","jir_og_description":"Announcement summarizing the latest information on number of shares acquired, total amount, period, and cumulative results for Mochida Pharmaceutical Co., Ltd.'s treasury stock acquisition.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-126625","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n